Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide

US11891401B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Yudong Cao · Hoherlehmer Straße, CN
• Siyi Jiang · Shanghai, CN
• Hongyong Kim · Hoherlehmer Straße, CN
• Andreas Kordikowski · Binningen, CH
• Irene Xia · Pudong New District, CN
• Bo Yu · Winchester, US
• Jing Zhang · Wantage, US
• Yi Zhao · South Pasadena, US

Key dates

• Filing date: Oct 8, 2019
• Grant date: Feb 6, 2024
• Expiry date: Jul 6, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application relates to N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (Compound I) fumaric acid co-crystals and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods of making the same; pharmaceutical compositions comprising them; and their use in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.